Market Research Logo

Global Hereditary Angioedema Therapeutics Market 2018-2022

Global Hereditary Angioedema Therapeutics Market 2018-2022

About Hereditary Angioedema Therapeutics

Hereditary angioedema is a rare genetic disease characterized by swelling of various parts of the body. The swelling is mainly observed in the face region and airways. It also leads to abdominal cramping.
Technavio’s analysts forecast the Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the hereditary angioedema therapeutics market. To calculate the market size, the report considers the revenue generated from the hereditary angioedema therapeutics.
Technavio's report, hereditary angioedema therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Key vendors

BioCryst Pharmaceuticals
Cipla
CSL
Pharming Group
Shire

Market driver

Increasing prevalence of hereditary angioedema
For a full, detailed list, view our report

Market challenge

High cost of treatment
For a full, detailed list, view our report

Market trend

Innovative treatment strategies
For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Hereditary Angioedema Therapeutics Market 2018-2022

Technavio recognizes the following companies as the key players in the hereditary angioedema therapeutics market: BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group, and Shire

Commenting on the report, an analyst from Technavio’s team said: “development of monoclonal antibody is one of the major trends in the market”. The development of therapeutics for the treatment of disease requires various approvals and experimentation. Shire after conducting clinical trials for the treatment of hereditary angioedema, launched the first monoclonal antibody, Lanadelumab (SHP643)

According to the report, one driver influencing this market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease in the future generation. Therefore, it is expected that the distribution of the disease and the demand for the therapeutics will increase during the coming years, which in turn, results in the growth of the global hereditary angioedema therapeutics market.

Further, the report states that one challenge affecting this market is the high cost of treatment. Although the medications for HAE is covered under patient healthcare schemes in most countries, the indirect costs associated with the treatment makes the treatment quite expensive for the patients, leading to less patient adherence.

Companies Mentioned

BioCryst Pharmaceuticals
Cipla
CSL
Pharming Group
Shire

  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global rare disease market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global - Market size and forecast 2017-2022 ($ mn)
      • Table Global - Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Pipeline landscape
    • Table Pipeline landscape by development phase
    • Table Key clinical trial candidates of hereditary angioedema
  • Market segmentation by product
    • Segmentation by product
      • Table Product - Market share 2017-2022 (%)
    • Comparison by product
      • Table Comparison by product
    • C1 inhibitors - Market size and forecast 2017- 2022
      • Table C1 inhibitors - Market size and forecast 2017-2022 ($ mn)
      • Table C1 inhibitors - Year-over-year growth 2018-2022 (%)
    • Icatibant - Market size and forecast 2017-2022
      • Table Icatibant - Market size and forecast 2017-2022 ($ mn)
      • Table Icatibant - Year-over-year growth 2018-2022 (%)
    • Ecallantide - Market size and forecast 2017-2022
      • Table Ecallantide - Market size and forecast 2017-2022 ($ mn)
      • Table Ecallantide - Year-over-year growth 2018-2022 (%)
    • Others - Market size and forecast 2017-2022
      • Table Others - Market size and forecast 2017-2022 ($ mn)
      • Table Others - Year-over-year growth 2018-2022 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global - Market share by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Americas - Market size and forecast 2017-2022
      • Table Americas - Market size and forecast 2017-2022 ($ mn)
      • Table Americas - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in Americas
    • EMEA - Market size and forecast 2017-2022
      • Table EMEA - Market size and forecast 2017-2022 ($ mn)
      • Table EMEA - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in EMEA
    • APAC - Market size and forecast 2017-2022
      • Table APAC - Market size and forecast 2017-2022 ($ mn)
      • Table APAC - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Innovative treatment strategies
    • Improved route of administration products
    • Development of monoclonal antibody
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • BioCryst Pharmaceuticals
      • Table BioCryst Pharmaceuticals: Overview
      • Table BioCryst Pharmaceuticals: Organizational developments
      • Table BioCryst Pharmaceuticals: Key offerings
      • Table BioCryst Pharmaceuticals: Key customers
    • Cipla
      • Table Cipla - Overview
      • Table Cipla - Business segments
      • Table Cipla - Organizational developments
      • Table Cipla - Geographic focus
      • Table Cipla - Segment focus
      • Table Cipla - Key offerings
      • Table Cipla - Key customers
    • CSL
      • Table CSL - Overview
      • Table CSL - Business segments
      • Table CSL - Organizational developments
      • Table CSL - Geographic focus
      • Table CSL - Segment focus
      • Table CSL - Key offerings
      • Table CSL - Key customers
    • Pharming Group
      • Table Pharming Group - Overview
      • Table Pharming Group - Business segments
      • Table Pharming Group - Organizational developments
      • Table Pharming Group - Geographic focus
      • Table Pharming Group - Key offerings
      • Table Pharming Group - Key customers
    • Shire
      • Table Shire - Overview
      • Table Shire - Business segments
      • Table Shire - Organizational developments
      • Table Shire - Geographic focus
      • Table Shire - Segment focus
      • Table Shire - Key offerings
      • Table Shire - Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report